AERI Awaits Data In Q3, FDA Approves Another TAF-based HIV Drug, CTIX On Watch

Aerie Pharmaceuticals Inc. (AERI) expects the 90-day topline interim efficacy readout from its first phase III trial for Roclatan, an investigational therapy for glaucoma, to be announced in the third quarter of 2016.

from RTT - Biotech http://ift.tt/1Lw64Lt
via IFTTT